Cutting-edge Management of Muscle-invasive Bladder Cancer in 2020 and a Glimpse into the Future

  • Malte W Vetterlein
  • J Alfred Witjes
  • Yohann Loriot
  • Gianluca Giannarini
  • Maarten Albersen
  • Maria J Ribal
  • Morgan Rouprêt
  • EAU Section of Oncological Urology (ESOU) Board

Related Research units

Abstract

This case-based discussion describes the clinical course of a 63-yr-old patient who presented with gross hematuria and was diagnosed with a muscle-invasive bladder cancer at transurethral resection. Computed tomography revealed a locally advanced tumor, and the patient underwent neoadjuvant chemotherapy followed by open radical cystectomy with standard pelvic lymph node dissection. In a step-by-step fashion, we elaborate on diagnostic and therapeutic treatment options from two different vantage points: (1) guideline-adherent treatment with the state-of-the-art standard of care, and (2) a glimpse into the future discussing the evidence of potential additional or alternative approaches based on recent scientific advances. PATIENT SUMMARY: In this case-based discussion, we follow the clinical course of a patient with advanced bladder cancer and elaborate how the state-of-the-art treatment looks like in 2020, based on the best available evidence. This is compared with potential future treatment strategies, which may change and alternate our understanding of optimal bladder cancer care.

Bibliographical data

Original languageEnglish
ISSN2588-9311
DOIs
Publication statusPublished - 12.2020
PubMed 32553706